本文選題：鼻咽癌 + 抗體　； 參考：《現(xiàn)代腫瘤醫(yī)學》2016年19期

【摘要】：目的:評價EB病毒(EBV)抗衣殼抗原VCA-IgA抗體、抗早期抗原EA-IgA抗體、抗立即早期抗原Rta-IgG抗體和EBV-DNA檢測在鼻咽癌診斷中的價值。方法:收集160例初治鼻咽癌,133例癥狀相似的非鼻咽癌患者和163名健康體檢者的血清和血漿。采用酶聯(lián)免疫法檢測血清VCA-IgA、EA-IgA和RtaIgG抗體的水平,用實時熒光定量PCR檢測血漿EBV-DNA的相對含量。按鼻咽癌2008臨床TNM分期法進行分期,計算不同分組、各臨床分期以及鼻咽癌治療前后的各抗體陽性率、抗體水平以及EB-DNA的檢測結(jié)果并進行數(shù)據(jù)分析。結(jié)果:鼻咽癌組VCA-IgA、EA-IgA、Rta-IgG和EBV-DNA陽性率均高于鼻咽相關(guān)疾病組及健康對照組(均P0.05)。血清VCA-IgA和EA-IgA結(jié)果相對A值(即r A或S/CO值)在Ⅰ、Ⅱ期低于Ⅲ、Ⅳ期,差異有統(tǒng)計學意義(P0.05),但陽性率在各期間比較差異無統(tǒng)計學意義(P0.05);Ⅰ、Ⅱ期患者Rta-IgG的r A值和陽性率明顯低于Ⅲ、Ⅳ期患者(P0.05);血漿中EBV-DNA陽性率及EBVDNA中位數(shù)水平隨著臨床分期的升高而增高,Ⅰ、Ⅱ期與Ⅲ、Ⅳ期比較差異有統(tǒng)計學意義(P0.05)。治療有效(CR+PR)患者的EBV-DNA含量明顯低于治療前水平(P0.05)。結(jié)論:VCA-IgA、EA-IgA、RtaIgG、EBV-DNA檢測有助于鼻咽癌的輔助診斷、臨床分期預測及療效評估。
[Abstract]:Objective: to evaluate the value of Epstein-Barr virus (EBV) anti-capsid antigen VCA-IgA antibody, anti-early antigen EA-IgA antibody, anti-immediate early antigen Rta-IgG antibody and EBV-DNA detection in the diagnosis of nasopharyngeal carcinoma. Methods: the serum and plasma of 160 patients with nasopharyngeal carcinoma (NPC) with similar symptoms, 133 patients with non nasopharyngeal carcinoma (NNPC) and 163 healthy controls were collected. The levels of serum VCA-IgAEA-IgA and RtaIgG antibodies were detected by enzyme-linked immunosorbent assay (Elisa), and the relative content of plasma EBV-DNA was detected by real-time fluorescence quantitative PCR. According to the clinical TNM staging method of nasopharyngeal carcinoma (NPC) 2008, the positive rate of antibody, the level of antibody and the detection results of EB-DNA were calculated and analyzed in different groups, clinical stages and before and after treatment of nasopharyngeal carcinoma. Results: the positive rates of VCA-IgAEA-IgAEA-IgAEA-Rta-IgG and EBV-DNA in nasopharyngeal carcinoma group were higher than those in nasopharyngeal related disease group and healthy control group (all P 0.05). The relative A value of serum VCA-IgA and EA-IgA (i.e. r A or S/CO) in stage 鈪，

本文編號：1819561